Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take aim at autoimmune kidney diseases

NCT ID NCT06285279

Recruiting now Disease control Sponsor: Nanjing University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This early-stage trial tests a new therapy called FKC289, which uses a patient's own immune cells engineered to target two proteins (BCMA and CD19) on cells that drive autoimmune attacks. The goal is to see if it is safe and can help control kidney diseases like lupus nephritis and ANCA-associated vasculitis in people who have not responded to standard treatments. Participants receive a single infusion of these modified cells after a short course of chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
FKC289 (BCMA/CD19 dual-targeted CAR-T cells)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat autoimmune kidney diseases, potentially reducing the need for long-term medications.
What could go wrong
This is an early, small Phase 1 trial focused on safety, so it may not lead to a proven treatment. Risks include severe side effects from the chemotherapy given before the cell infusion and the CAR-T cells themselves.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis granulomatosis with polyangiitis Immunoglobulin G4-Related Disease immunoglobulin G4-related sclerosing disease lupus nephritis membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA-ASSOCIATED VASCULITIS IGG4-RELATED DISEASES LUPUS NEPHRITIS MEMBRANOUS NEPHROPATHY - PLA2R INDUCED

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Jinling Hospital

    RECRUITING

    Nanjing, Jiangsu, 210016, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.